Eli Lilly CEO Dave Ricks said Monday that Foundayo now accounts for one in three new oral weight loss drug starts in the United States, with the pill capturing a larger slice of that market each week. Dave Ricks made the remarks in an exclusive interview with CNBC. "We're confident long term" about Lilly's place in the pill segment, Dave Ricks told CNBC, noting that Foundayo rollouts in additional countries are planned for later this year. The comments came as Lilly broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas — nearly a year after first announcing the project. The plant is expected to be operational by 2030, the company said.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.